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Abstract
Myriad experiments have identified an important role for CD8+ T cell response mechanisms in
determining recovery from influenza A virus infection. Animal models of influenza infection
further implicate multiple elements of the immune response in defining the dynamical charac-
teristics of viral infection. To date, influenza virus models, while capturing particular aspects
of the natural infection history, have been unable to reproduce the full gamut of observed viral
kinetic behaviour in a single coherent framework. Here, we introduce a mathematical model
of influenza viral dynamics incorporating all major immune components (innate, humoral and
cellular) and explore its properties with a particular emphasis on the role of cellular immunity.
Calibrated against a range of murine data, our model is capable of recapitulating observed viral
kinetics from a multitude of experiments. Importantly, the model predicts a robust exponential
relationship between the level of effector CD8+ T cells and recovery time, whereby recovery
time rapidly decreases to a fixed minimum recovery time with an increasing level of effec-
tor CD8+ T cells. We find support for this relationship in recent clinical data from influenza
A(H7N9) hospitalised patients. The exponential relationship implies that people with a lower
level of naive CD8+ T cells may receive significantly more benefit from induction of additional
effector CD8+ T cells arising from immunological memory, itself established through either
previous viral infection or T cell-based vaccines.
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Introduction
Invasion of influenza virus into a host’s upper respiratory tract leads to infection of healthy
epithelial cells and subsequent production of progeny virions (1). Infection also triggers a
variety of immune responses. In the early stage of infection a temporary non-specific response
(innate immunity) contributes to the rapid control of viral growth while in the late stage of
infection, the adaptive immune response dominates viral clearance (2). The early immune
response involves production of antiviral cytokines and cells, e.g. type 1 interferon (IFN) and
natural killer cells (NK cells), and is independent of virus type (3, 4, 5, 6, 7). In the special case
of a first infection in a naive host, the adaptive immune response, mediated by the differentiation
of naive T cells and B cells and subsequent production of virus-specific T cells and antibodies
(8, 2), leads to not only a prolonged killing of infected cells and virus but also the formation
of memory cells which can generate a rapid immune response to secondary infection with the
same virus (9, 10).
CD8+ T cells, which form a major component of adaptive immunity, play an important role
in efficient viral clearance (11). However, available evidence suggests they are unable to clear
virus in the absence of antibodies (12, 13) except in hosts with a very high level of pre-existing
naive or memory CD8+ T cells (14, 15, 16). Some studies indicate that depletion of CD8+ T
cells could decrease the viral clearance rate and thus prolong the duration of infection (17, 18,
19, 20). Furthermore, a recent study of human A(H7N9) hospitalized patients has implicated
the number of effector CD8+ T cells as an important driver of the duration of infection (21).
This diverse experimental and clinical data, sourced from a number of host-species, indicates
that timely activation and elevation of CD8+ T cell levels may play a major role in the rapid
and successful clearance of influenza virus from the host. These observations motivate our
modeling study of the role of CD8+ T cells in influenza virus clearance.
Viral dynamics models have been extensively applied to the investigation of the antiviral
mechanisms of CD8+ T cell immunity against a range of pathogens, with major contributions
for chronic infections such as HIV/SIV (22, 23, 24, 25, 26, 27), HTLV-I (28) and chronic
LCMV (29, 30). However, for acute infections such as measles (31) and influenza (32, 33, 34,
35, 36, 37, 38, 39, 40, 41, 42), highly dynamical interactions between the viral load and the
immune response occur within a very short time window, presenting new challenges for the
development of models incorporating CD8+ T cell immunity.
Existing influenza viral dynamics models, introduced to study specific aspects of influenza
infection, are limited in their ability to capture all major aspects of the natural history of in-
fection, hindering their use in studying the role of CD8+ T cells in viral clearance. Some
models show a severe depletion of target cells (i.e healthy epithelial cells susceptible to viral
infection) after viral infection (34, 36, 37, 38, 40). Depletion may be due to either infection or
immune-mediated protection. Either way, these models are arguably incompatible with recent
evidence that the host is susceptible to re-infection with a second strain of influenza a short
period following primary exposure (43). Furthermore, as reviewed by Dobrovolny et al. (39),
target cell depletion in these models strongly limits viral expansion so that virus can be effec-
tively controlled or cleared at early stage of infection even in the absence of adaptive immunity,
which contradicts the experimental finding that influenza virus remains elevated in the absence
of adaptive immune response (44). While a few models do avoid target cell depletion (32, 33),
they either assume immediate replenishment of target cells (32) or a slow rate of virus invasion
into target cells resulting in a much delayed peak of virus titer at day 5 post-infection (rather
than the observed peak at day 2) (33). Moreover, models with missing or unspecified major im-
mune components, e.g. no innate immunity (24, 25, 36, 38), no antibodies (24, 25, 33, 41, 42)
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or unspecified adaptive immunity (40), also indicate the need for further model development.
For an in-depth review of the current virus dynamics literature on influenza, we refer the reader
to the excellent article by Dobrovolny et al. (39).
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Figure 1: Schematic diagram showing the major components of viral infection and the immune
response. Infection starts when virus binds to healthy epithelial cells (target cells). Infected
cells release new virus and produce cytokines such as IFN. IFN is a major driver of innate
immunity, responsible for effective control of rapid viral growth and expansion. Virus further
stimulates naive CD8+ T cells and B cells to produce effector CD8+ T cells and antibodies,
responsible for final clearance of virus.
In this paper, we construct a within-host model of influenza viral dynamics in naive (i.e.
previously unexposed) hosts that incorporates the major components of both innate and adap-
tive immunity and use it to investigate the role of CD8+ T cells in influenza viral clearance.
The model is calibrated against a set of published murine data from Miao et al. (38) and is then
validated through demonstration of its ability to qualitatively reproduce a range of published
data from immune-knockout experiments (12, 17, 18, 44, 13, 38). Using the model, we find that
the recovery time — defined to be the time when virus titer first drops below a chosen threshold
in the (deterministic) model — is negatively correlated with the level of effector CD8+ T cells
in an approximately exponential manner. To the best of our knowledge, this relationship, with
support in both H3N2-infected mice and H7N9-infected humans (21), has not been previously
identified. The exponential relationship between CD8+ T cell level and recovery time is shown
to be remarkably robust to variation in a number of key parameters, such as viral production
rate, IFN production rate, delay of effector CD8+ T cell production and the level of antibodies.
Moreover, using the model, we predict that people with a lower level of naive CD8+ T cells
may receive significantly more benefit from induction of additional effector CD8+ T cells. Such
production, arising from immunological memory, may be established through either previous
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viral infection or T cell-based vaccines.
Methods
The model
The model of primary viral infection is a coupled system of ordinary and delay differential
equations, consisting of three major components (see Fig. 1 for a schematic diagram). Eqs. 1–3
describe the process of infection of target cells by influenza virus and are a major component in
almost all models of virus dynamics in the literature. Eqs. 4 and 5 model IFN-mediated innate
immunity (45, 46). Thirdly, adaptive immunity including CD8+ T cells and B cell-produced
antibodies for killing infected cells and neutralizing influenza virus respectively are described
by Eqs. 6–11.
dV
dt = pV I−δVV −κSVAS−κLVAL−βV T, (1)
dT
dt = gT (T +R)(1−
T +R+ I
T0
)−β ′VT +ρR−φFT, (2)
dI
dt = β
′VT −δII−κNIF−κE IE, (3)
dF
dt = pF I−δFF, (4)
dR
dt = φFT −ρR, (5)
dCn
dt =−βCn(
V
V +hC
)Cn, (6)
dE
dt = βCn(
V (t− τC)
V (t− τC)+hC
)Cn(t− τC)e(pCτC)−δEE, (7)
dBn
dt =−βBn(
V
V +hB
)Bn, (8)
dP
dt = βBn(
V (t− τB)
V (t− τB)+hB
)Bn(t− τB)e(pBτB)−δPP, (9)
dAS
dt = pSP−δSAS, (10)
dAL
dt = pLP−δLAL. (11)
In further detail, Eq. 1 indicates that the change in viral load (V ) is controlled by four
factors: the production term (pV I) in which virions are produced by infected cells (I) at a rate
pV (47, 37, 45); the viral natural decay/clearance (δVV ) with a decay rate of δV ; the viral
neutralisation terms (κSVAS and κLVAL) by antibodies (both a short-lived antibody response
AS driven by, e.g. IgM, and a longer-lived antibody response AL driven by, e.g. IgG and IgA
(12, 38)), and a consumption term (βVT ) due to binding to and infection of target cells (T ).
In Eq. 2, the term gT (T +R)(1− (T +R+ I)/T0) models logistic regrowth of the target cell
pool (46). Both target cells (T ) and resistant cells (R, those protected due to IFN-induced
antiviral effect) can produce new target cells, with a net growth rate proportional to the severity
of infection, 1−(T +R+ I)/T0 (i.e. the fraction of dead cells). T0 is the initial number of target
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cells and the maximum value for the target cell pool (34). Target cells (T ) are consumed by
virus (V ) due to binding (β ′VT ), the same process as βV T . Note that β and β ′ have different
measurement units due to different units for viral load (V ) and infected cells (I). As already
mentioned, the innate response may trigger target cells (T ) to become resistant (R) to virus,
at rate φFT . Resistant cells lose protection at a rate ρ (45). This process also governs the
evolution of virus-resistant cells (R) in Eq. 5.
Eq. 3 describes the change of infected cells (I). They increase due to the infection of target
cells by virus (β ′VT ) and die at a (basal) rate δI . Two components of the immune response
increase the rate of killing of infected cells. IFN-activated NK cells kill infected cells at a rate
κNIF (48, 6, 45, 46). Effector CD8+ T cells (E) — produced through differentiation from naive
CD8+ T cells Cn in Eq. 6 — kill at a rate κEIE. Of note our previous work has demonstrated
that models of the innate response containing only IFN-induced resistance for target cells (state
R; Eq. 5), while able to maintain a population of healthy uninfected cells, still control viral
kinetics through target cell depletion, and therefore cannot reproduce viral re-exposure data
(46, 43). Given our interest in analysing a model that prevents target cell depletion, inclusion
of IFN-activated NK cells (term κNIF) is an essential part of the model construction.
Eq. 4 models the innate response, as mediated by IFN (F). IFN is produced by infected
cells at a rate pF and decays at a rate δF (46).
Eq. 6 models stimulation of naive CD8+ T cells (Cn) into the proliferation/differentiation
process by virus at a rate βCnV/(V + hC)), where βCn is the maximum stimulation rate and
hC indicates the viral load (V ) at which half of the stimulation rate is achieved. Note that this
formulation does not capture the process of antigen presentation and CD8+ T cell activation,
but rather is a simple way to establish the essential coupling between the viral load and the rate
of CD8+ T cell activation in the model (49). In Eq. 7, the production of effector CD8+ T cells
(E) is assumed to be an “advection flux” induced by a delayed virus-stimulation of naive CD8+
T cells (the first term on the righthand side of Eq. 7). The delayed variables, V (t − τC) and
Cn(t− τC), equal zero when t < τC. The introduction of the delay τC is to phenomenologically
model the delay induced by both naive CD8+ T cell proliferation/differentiation and effector
CD8+ T cell migration and localization to the site of infection for antiviral action (50, 51,
42). The delay also captures the experimental finding that naive CD8+ T cells continue to
differentiate into effector T cells in the absence of ongoing antigenic stimulation (49, 52). The
multiplication factor epCτC indicates the number of effector CD8+ T cells produced from one
naive CD8+ T cell, where pC is the average effector CD8+ T cell production rate over the
delay period τC. The exponential form of the multiplication factor is derived based on the
assumption that cell differentiation and proliferation follows a first-order advection–reaction
equation. Effector CD8+ T cells decay at a rate δE .
Similar to CD8+ T cells, Eqs. 8 and 9 model the proliferation/differentiation of naive B
cells, stimulated by virus presentation at rate βBnV/(V +hB). Stimulation subsequently leads
to production of plasma B cells (P) after a delay τB. The multiplication factor epBτB indicates
the number of plasma B cells produced from one naive B cell, where pB is the production rate.
Plasma B cells secrete antibodies, which exhibit two types of profiles in terms of experimental
observation: a short-lived profile (e.g. IgM lasting from about day 5 to day 20 post-infection)
and a longer-lived profile (e.g. IgG and IgA lasting weeks to months) (12, 38). These two
antibody responses are modeled by Eqs. 10 and 11 wherein different rates of production (PS
and PL) and consumption (δS and δL) are assumed.
6
Model parameters and simulation
The model contains 11 equations and 30 parameters (see Table 1). This represents a serious
challenge in terms of parameter estimation, and clearly prevents a straightforward application
of standard statistical techniques. To reduce uncertainty, a number of parameters were taken
directly from the literature, as per the citations in Table. 1. The rest were estimated (as indi-
cated in Table 1) by calibrating the model against the published data from Miao et al. (38)
who measured viral titer, CD8+ T cell counts and IgM and IgG antibodies in laboratory mice
(exhibiting a full immune response) over time during primary influenza H3N2 virus infection
(see (38) for a detailed description of the experiment). The approach to estimating the param-
eters based on Miao et al.’s data is provided in the Supplementary Material and the estimated
parameter values are given in Table 1. Note that the data were presented in scatter plots in the
original paper (38), while we presented the data here in Mean ± SD at each data collection
time point for a direct comparison with our mean-field mathematical model.
For model simulation, the initial condition is set to be (V,T, I,F,R,Cn,E,Bn,P,AS,AL) =
(V0,T0,0,0,0,100,0,100,0,0,0) unless otherwise specified. The initial target cell number (T0)
was estimated by Petrie et al. (53). We estimate that of order 100 cells (resident in the spleen)
are able to respond to viral infection (Cn) (personal communication, N. LaGruta, Monash Uni-
versity, Australia). Note that 100 naive CD8+ T cells might underestimate the actual number of
naive precursors that could respond to all the epitopes contained within the virus but does not
qualitatively alter the model dynamics and predictions (see Results where the naive CD8+ T
cell number is varied between 0 to 200). In the absence of further data, we also use this value for
the initial naive B cell number (Bn), but again this choice does not qualitatively alter the model
predictions. The numerical method and code (implemented in MATLAB, version R2014b, the
MathWorks, Natick, MA) for solving the model are provided in the Supplementary Material.
Analysis of clinical influenza A(H7N9) data
Clinical influenza A(H7N9) patient data was used to test our model predictions on the relation-
ship between CD8+ T cell number and recovery time. The data was collected from 12 surviving
patients infected with H7N9 virus during the first wave of infection in China in 2013 (raw data
is provided in Dataset S1; see the paper of Wang et al. (21) for details of data collection; this
study was reviewed and approved by the SHAPHC Ethics Committee). Note that the clinical
data were scarce for some patients. For those patients, we have assumed that the available data
are representative of the unobserved values in the neighboring time period. For each patient,
we took the average IFNγ+ CD8+ T cell number in 106 peripheral blood mononuclear cells
(PBMC) for the period from day 8 to day 22 (or the recovery day if it comes earlier) post-
admission as a measure of the effector CD8+ T cell level. This period was chosen a priori as it
roughly matches the duration of the CD8+ T cell profile and clinical samples were frequently
collected in this period. The average CD8+ T cell count was given by the ratio of the total area
under the data points (using trapezoidal integration) to the number of days from day 8 to day 22
(or the recovery day if it comes earlier). For those patients for which samples at days 8 and/or
22 were missing we specified the average CD8+ T cell level at the missing time point to be
equal to the value from the nearest sampled time available.
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Figure 2: The model with estimated parameters (solid curves) captures the murine data from
the paper by Miao et al.(38). The data is shown with error bars (Mean±SD). Note that due to
the limit of detection for the viral load (occurring after 10 days post-infection as seen in viral
load data), the last three data points in the upper-left panel were not taken into consideration
for model fitting.
Results
Model properties and reproduction of published experimental data
We first analyze the model behavior in order to establish a clear understanding of the model
dynamics. Fig. 2 shows solutions (time-series) for the model compartments (viral load, CD8+
T cells and IgM and IgG antibody) calibrated against the murine data from (38). Solutions
for the remaining model compartments are shown in Fig. 3. The model (with both innate and
adaptive components active) prevents the depletion of target cells (see Fig. 3 wherein over 50%
of target cells remain during infection) and results in a minor loss of just 10–20% of healthy
epithelial cells (i.e. the sum of target cells (T ) and virus-resistant cells (R); see Supplementary
Fig. S1). The primary driver for the maintenance of the target cell pool during acute viral
infection is a timely activation of the innate immune response, and in particular the natural killer
cells (Supplementary Fig. S2). Since we have previously shown that the target-cell limited
model (even with the resistant cell compartment) is unable to reproduce observations from
heterologous re-exposure experiments (43, 46), our model improves upon previous models
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Figure 3: Model solution with parameters given in Table 1. Time courses of viral load (V ),
effector CD8+ T cells (E), short-lived antibody response (AS) and long-lived antibody response
(AL) have been shown in Fig. 2.
where viral clearance was only achieved through depletion of target cells (a typical solution
shown in Supplementary Fig. S2b). Importantly, our result is distinguished from that of Saenz
et. al. (37), wherein the healthy cell population was similarly maintained, but primarily through
induction of the virus-resistant state, thereby rendering that model incapable of capturing re-
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infection behavior as established in animal models (43).
The modeled viral dynamics exhibits three phases, each dominated by the involvement of
different elements of the immune responses (Fig. 4). Immediately following infection (0–2 days
post-infection) and prior to the activation of the innate (and adaptive) immune responses, virus
undergoes a rapid exponential growth (Fig. 4a). In the second phase (2–5 days post-infection),
the innate immune response successfully limits viral growth (Fig. 4a). In the third phase (4–6
days post-infection), adaptive immunity (antibodies and CD8+ T cells) is activated and viral
load decreases rapidly, achieving clearance. Figs. 4b and 4c demonstrate the dominance of
the different immune mechanisms at different phases. In Fig. 4b models with and without
immunity are indistinguishable until day 2 (shaded region), before diverging dramatically when
the innate and then adaptive immune responses influence the dynamics. In Fig. 4c, models
with and without an adaptive response only diverge at around day 4 as the adaptive response
becomes active. We have further shown that this three-phase property is a robust feature of the
model, emergent from its mathematical structure and not a property of fine tuning of parameters
(see Supplementary Fig. S3). Importantly, it clearly dissects the periods and effect of innate
immunity, extending on previous studies of viral infection phases where the innate immune
response was either ambiguous or ignored (12, 54, 38).
As reviewed by Dobrovolny et al. (39), a number of in vivo studies have been performed
to dissect the contributions of CD8+ T cells and antibodies (12, 17, 18, 44, 55). We use the
findings of these studies to validate our model, by testing how well it is able to reproduce the
experimental findings (without any further adjustment to parameters). Although the determi-
nation of the role of CD8+ T cells is often hindered by co-inhibition of both CD8+ T cells
and the long-lived antibody response (e.g. using nude mice), it is consistently observed that
antibodies play a dominant role in final viral clearance while CD8+ T cells are primarily re-
sponsible for the timely killing of infected cells and so indirectly contribute to an increased rate
of removal of free virus towards the end of infection (17, 18, 13). Furthermore, experimental
data demonstrate that a long-lived antibody response is crucial for achieving complete viral
clearance, while short-lived antibodies are only capable of driving a transient decrease in viral
load (12, 44). We find that our model (with parameters calibrated against Miao et al.’s data
(38)) is able to reproduce these observations:
• virus can rebound in the absence of long-lived antibody response (see Fig. 5 and Supple-
mentary Fig. S4).
• both the CD8+ T cell response and short-lived antibody response only facilitate a faster
viral clearance, and are incapable of achieving clearance in the absence of long-lived
antibody response (see Fig. 5 and Supplementary Fig. S4).
• a lower level of CD8+ T cells (modulated by a decreased level of initial naive CD8+ T
cells, Cn) significantly prolongs the viral clearance (see Supplementary Fig. S4).
In addition, the model also predicts a rapid depletion of naive CD8+ T cells after primary
infection (see Fig. 3), which represents a full recruitment of naive CD8+ T cell precursors.
This result may be associated with the experimental evidence suggesting a strong correlation
between the naive CD8+ T cell precursor frequencies and effector CD8+ T cell magnitudes
for different pMHC-specific T cell populations (56). Note that in Fig. 5 no adjustments to
the model (e.g. to the vertical scale) were made; its behavior is completely determined by the
calibration to the aforementioned murine data (38) and so these findings represent a (successful)
prediction of the model.
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Figure 4: The model solution exhibits three-phase behavior following influenza virus infection.
Panel (a) schematically represents these three-phases of behavior based on involvement of im-
mune responses. Following infection, virus first undergoes rapid exponential growth before the
innate immune response is activated (on day 2). Innate immunity controls rapid viral expansion
to form a plateau in viral load. Adaptive immunity starts to take effect 4–6 days post-infection
and is responsible for viral clearance. Panels (b) and (c) demonstrate that the model dynam-
ics follow the three-phase theory. Viral kinetics in the presence of a full immune response is
shown by the solid line (in (b) and (c)). In panel (b), the dashed line shows viral kinetics in
the complete absence of immunity (innate and adaptive; by letting pF = 0 and βCn = βBn = 0
in the model). The trajectories overlap prior to the activation of the innate response, before
diverging due to target cell depletion. The shaded region highlights the first phase (exponential
growth). In panel (c), the dashed line shows viral kinetics in the absence of adaptive immunity
(by letting βCn = βBn = 0; innate immunity remains active). The trajectories overlap prior to
the activation of the adaptive response. The shaded region highlights the second phase (innate
response). Note: changes in model parameters shifts where the three phases occur, but does
not alter the underlying three-phase structure. i.e. existence of the three phases is robust to
variation in parameters (see Supplementary Material and Supplementary Fig. S3 in particular).
In summary, we have demonstrated that our model—with parameters calibrated against
murine data (38)—exhibits three important phases characterized by the involvement of various
immune responses. Advancing on previous models, our model does not rely on target cell
depletion, and successfully reproduces a multitude of behavior from knockout experiments
where particular components of the adaptive immune response were removed. This provides
us with some confidence that each of the major components of the immune response has been
captured adequately by our model, allowing us to now make predictions on the effect of the
cellular adaptive response on viral clearance.
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Figure 5: Consistency between mice data (left panels) and model results (right panels) shows
that short-lived antibody response (e.g. IgM) is only capable of generating a transient decrease
in viral load while long-lived antibody response (e.g. IgA) plays a more dominant role in
late-phase viral clearance. (a) Data is from the paper of Kris et al. (44). Normal or nude
BALB/c mice were infected with H3N2 virus. External antibodies were given at day 5 and
had waned by about day 21. The model simulation mimics the passive antibody input by
introducing an extra amount of IgM (in addition to antigen-stimulated IgM), whose time course
faithfully follows the experimental measurement (see Fig. 2a in the paper of Kris et al. (44)).
“CD8+ T-, IgA-, IgG-” was modeled by letting βCn = 0 and pL = 0. “External IgM” (in
addition to the IgM produced by plasma cells) was modeled by adding a new term −κSVAe(t)
to Eq. 1 where Ae(t) follows a piecewise function Ae(t) = 0 for t < 5, Ae(t) = 100(t−5) for
t ∈ [5,7), Ae(t) = 200− 14(t − 7) for t ∈ [7,21) and Ae(t) = 0 for t ≥ 21. (b) Data is from
the paper of Iwasaki et al. (12). The data indicates that the long-lasting IgA response, but
not the long-lasting IgG response or the short-lasting IgM response, is necessary for successful
viral clearance. “No long-lived antibody response” was modeled by letting pL = 0. Note that
Miao et al. only measured IgM and IgG, but not IgA. As such, our model’s long-lived antibody
response was calibrated against IgG kinetics (see Fig. 2). Therefore, we emphasise that we can
only investigate the relative contributions of short-lived and long-lived antibodies.
Dependence of the recovery time on the level of effector CD8+ T cells
Having established that our model is (from a structural point of view) biologically plausible
and that our parameterization is capable of reproducing varied experimental data under differ-
ent immune conditions (i.e. knockout experiments), we now study how the cellular adaptive
response influences viral kinetics in detail. We focus on the key clinical outcome of recov-
ery time, defined in the model as the time when viral titer first falls below 1 EID50/ml, the
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minimum value detected in relevant experiments (e.g. Fig. 2).
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Figure 6: The level of effector CD8+ T cells plays an important role in determining recovery
time. Recovery time is defined to be the time when viral load falls to 1 EID50/ml. Panel (a)
shows that the average effector CD8+ T cell number over days 6–20 is linearly related to the
naive CD8+ T cell number (i.e. Cn(0)). Panel (b) shows that the recovery time is approximately
exponentially related to the initial naive CD8+ T cell number. Combined, these results give
panel (c) wherein an approximately exponential relationship is observed between the average
CD8+ T cell number and recovery time, both of which are experimentally measurable. Note
that the exponential/linear fits shown in the figures are not generated by the viral dynamics
model but are used to indicate the trends (evident visually) in the model’s behavior. Panel (d)
shows that varying the delay τC (in a similar way to that shown in Fig. S5 in the Supplementary
Material), rather than the naive CD8+ T cell number, does not alter the exponential relationship.
In panel (d), the crosses represent the results of varying τC and the empty circles are the same
as those in panel (c) for comparison.
Time series of the viral load show that the recovery time decreases as the initial naive CD8+
T cell number (Cn) increases (Supplementary Fig. S4). With that in mind, we now examine
how recovery time is associated with the clinically relevant measure of effector CD8+ T cell
level during viral infection. With an increasing initial level of naive CD8+ T cells, the average
level of effector CD8+ T cells over days 6–20 increases linearly (Fig. 6a), while the recovery
time decreases in an approximately exponential manner (Fig. 6b). Combining these two effects
gives rise to an approximately exponential relation between the level of effector CD8+ T cells
and recovery time (Fig. 6c). Note that the exponential/linear fits shown in the figures are simply
to aid in interpretation of the results. They are not generated by the viral dynamics model.
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If varying the delay for naive CD8+ T cell activation and differentiation, τC, while keeping
the naive CD8+ T cell number fixed (at the default value of 100), we find that the average level
of effector CD8+ T cells is exponentially related to the delay, while the recovery time is depen-
dent on the delay in a piecewise linear manner (see Supplementary Fig. S5). Nevertheless, the
combination still leads to an approximately exponential relationship between the level of effec-
tor CD8+ T cells and recovery time (Supplementary Fig. S6), which is almost identical to that
of varying naive CD8+ T cells (Fig. 6d). We also examine the sensitivity of the exponential
relationship to other model parameters generally accepted to be important in influencing the
major components of the system, such as the viral production rate pV , IFN production rate pF
and naive B cell number. We find that the exponential relationship is robust to significant vari-
ation in all of these parameters (see Supplementary Figs. S6 and S7 and Fig. 9). These results
suggest that a higher level of effector CD8+ T cells is critical for early recovery, consistent with
experimental findings (57).
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Figure 7: Clinical A(H7N9) data exhibits an exponential relationship between the average
CD8+ T cell number and recovery time. The x-axis is the average level of functional ef-
fector CD8+ T cells (i.e. IFNγ+ CD8+ T cells) over the period from day 8 to day 22
(or the recovery day if it comes earlier). Spearman’s rank correlation test indicates a sig-
nificant negative correlation between the average CD8+ T cell numbers and recovery time
(ρ = −0.8368, p = 0.0013). Excluding one of the patients (No. a79 in Dataset S1; discussed
in the Discussion), all other data points (solid dots) are fitted by an offset exponential function
y = 24.8755e−0.0073x +17.5356, indicating that the best achievable recovery time for individu-
als with a high CD8+ T cell response is approximately 17.5356.
Finally, and perhaps surprisingly given our model has been calibrated purely on data from
the mouse, a strikingly similar relationship as shown in Fig. 6c is found in clinical data from
influenza A(H7N9) virus-infected patients (Fig. 7). Excluding one patient (No. a79 in Dataset
S1; the exclusion is considered further in the Discussion), average IFNγ+ CD8+ T cells and re-
covery time are negatively correlated (Spearman’s ρ =−0.8368, p= 0.0013) and well captured
by an exponential fit with an estimated offset (see Fig. 7 caption for details). The exponential
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relationship (observed in both model and data) has features of a rapid decay for relatively
low/intermediate levels of effector CD8+ T cells and a strong saturation for relatively high
CD8+ T levels, implying that even with a very high level of naive CD8+ T cells, recovery time
can not be reduced below a certain value (in this case, estimated to be approximately 17 days).
Of course, the exponential relationship (i.e. the scale of CD8+ T cell level or recovery time),
is only a qualitative one, as we have no way to determine the scaling between different x-axis
measurement units, nor adjust for particular host and/or viral factors that differ between the two
experiments (i.e. H3N2-infection in the mouse (38) versus H7N9-infeciton in humans (21)).
Dependence of the recovery time on the level of memory CD8+ T cells
In addition to naive CD8+ T cells, memory CD8+ T cells (established through previous viral
infection) may also significantly affect recovery time due to both their rapid activation upon
antigen stimulus and faster replication rate (58, 59, 60, 61). To study the role of memory CD8+
T cells, we must first extend our model. As we are only concerned with how the presence of
memory CD8+ T cells influences the dynamics, as opposed to the development of the memory
response itself, the model is modified in a straightforward manner through addition of two
additional equations which describe memory CD8+ T cell (Cm) proliferation/differentiation:
dCm
dt =−βCm(
V
V +hCm
)Cm, (12)
dEm
dt = βCm(
V (t− τCm)
V (t− τCm)+hCm
)Cm(t− τCm)e(pCmτCm)−δEEm. (13)
Accordingly the term κEIE in Eq. 3 is modified to κEI(E +Em). The full model and details
on the choice of the additional parameters are provided in the Supplementary Material. Note
that the model component, Cm, may include different populations of memory CD8+ T cells,
including those directly specific to the virus and those stimulated by a different virus but which
provide cross-protection (62, 63).
Fig. 8a shows how the pre-existing memory CD8+ T cell number (Cm) changes the ex-
ponential relationship between naive CD8+ T cells and recovery time. Importantly, as the
number of memory CD8+ T cells increases, the recovery time decreases for any level of naive
CD8+ T cells and the exponential relationship remains. The extent of reduction in the recovery
time for a relatively low level of naive CD8+ T cells is greater than that for a relatively high
level of naive CD8+ T cells. This suggests that people with a lower level of naive CD8+ T
cells may benefit more through induction of memory CD8+ T cells, emphasizing the potential
importance for taking prior population immunity into consideration when designing CD8+ T
cell-based vaccines (64).
The above result is based on the assumption that the initial memory CD8+ T cell number
upon re-infection is independent of the number of naive CD8+ T cells available during the
previous infection. However, it has also been found that the stationary level of memory CD8+
T cells is usually maintained at about 5–10% of the maximum antigen-specific CD8+ T cell
number during primary viral infection (8, 65). This indicates that people with a low naive CD8+
T cell number may also develop a low level of memory CD8+ T cells following infection. In
consequence, such individuals may be relatively more susceptible to viral re-infection (66).
This alternative and arguably more realistic relationship between the numbers of naive and
memory CD8+ T cells is simulated in Fig. 8b where memory CD8+ T cell levels are set to 5%
of the maximum of the effector CD8+ T cell level. Results suggest that, upon viral re-infection,
pre-existing memory CD8+ T cells are able to significantly improve recovery time except for
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Figure 8: Effects of naive and memory CD8+ T cells on viral clearance. Recovery time is
defined to be the time when the viral load falls to 1 EID50/ml. Panel (a) demonstrates that
varying the number of memory CD8+ T cells (Cm) reduces the recovery time for any naive
CD8+ T cell number (i.e. Cn(0)). Note that saturation is observed for Cm > 100 where the
recovery time is about 6 days, independent of the naive cell numbers. Panel (b) demonstrates
how the presence of pre-existing memory CD8+ T cells (solid dots) leads to a shorter recovery
time when compared to the case where no memory CD8+ T cells are established (open circles).
Note the time scale difference in panels (a) and (b). This simulation is based on the assumption
that the level of pre-existing memory CD8+ T cells is assumed to be either 1% or 5% (as
indicated in the legend) of the maximum effector CD8+ T cell number due to primary viral
infection. The memory cell number (which is not shown in this figure) is about 30 time as
many as the naive cell number shown in the figure, i.e. 30 naive cells result in about 900
memory cells before re-infection.
in hosts with a very low level of naive CD8+ T cells (Fig. 8b). This is in accordance with
the assumption that a smaller naive pool leads to a smaller memory pool and in turn a weaker
shortening in recovery time. Although the model suggests that the failure of memory CD8+
T cells to protect the host is unlikely to be observed (because of the approximately 30 fold
increase in the size of the memory pool relative to the naive pool), the failure range may be
increased if the memory pool size is much smaller (modulated by, say, changing 5% to 1% in
the model). Therefore, for people with a low naive CD8+ T cell number, the level of memory
CD8+ T cells may be insufficient and prior infection may provide very limited benefit, further
emphasizing the opportunity for novel vaccines that are able to induce a strong memory CD8+
T cell response to improve clinical outcomes.
Dependence of the recovery time on antibody level
Antibodies appear at a similar time as effector CD8+ T cells during influenza viral infection
and may enhance the reduction in the recovery time in addition to CD8+ T cells. By varying
the naive B cell number Bn (as a convenient, but by no means unique, way to influence antibody
level), we find that increasing the antibody level shortens the recovery time regardless of the
initial naive CD8+ T cell number, leaving the exponential relation largely intact (Fig. 9). A
slight saturation occurs for the case in which levels of both naive B cells and CD8+ T cells are
low. Moreover, variation in naive B cell number also results in a wider variation in recovery
time for a lower naive CD8+ T cell level, suggesting that people with a lower level of naive
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Figure 9: Influence of antibody level on the relationship between the naive CD8+ T cell number
and recovery time. Recovery time is defined to be the time when viral load falls to 1 EID50/ml.
Different antibody levels are simulated by varying the initial number of naive B cells (i.e. Bn at
t = 0).
CD8+ T cells may, once again, receive a more significant benefit (in terms of recovery time)
through effective induction of an antibody response via vaccination.
Discussion
In this paper, we have studied the role of CD8+ T cells in clearing influenza virus from the
host using a viral dynamics model. The model was calibrated on a set of published murine data
from Miao et al. (38) and has been further shown to be able to reproduce a range of published
data from experiments with different immune components knocked out. By avoiding target-
cell depletion, our model is also compatible with re-infection data (43), providing a strong
platform on which to examine the role of CD8+ T cells in determining recovery time from
infection. Our primary finding is that the time of recovery from influenza viral infection is
negatively correlated with the level of effector CD8+ T cells in an approximately exponential
manner. This robust property of infection has been identified from the model when calibrated
against influenza A(H3N2) infection data in mice (38), but also observed in clinical case series
of influenza A(H7N9) infection in humans (Fig. 7) (21). Our findings, in conjunction with
conclusions on the potential role for a T cell vaccine that stimulates and/or boosts the memory
response, suggest new directions for research in both non-human species and further studies in
humans on the association between CD8+ T cell levels and clinical outcomes. Further research,
including detailed statistical fitting of our model to an extensive panel of infection data (as yet
unavailable) from human and non-human species, is required to establish the generality of these
relationships and provide quantitative insights for specific viruses in relevant hosts.
The non-linear relationship between effector CD8+ T cell level and recovery time may be
useful in clinical treatment. The saturated property of the relation implies that a linear increase
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in the effector CD8+ T cell level may result in diminishing incremental improvements in patient
recovery times. With evidence of a possible age-dependent loss of naive T cells (67, 68, 69),
our model results imply that boosting the CD8+ T cell response via T cell vaccination may
be particularly useful for those with insufficient naive CD8+ T cells. The population-level
consequences of such boosting strategies, while beyond the scope of this work, have previously
been considered by the authors (64).
We also investigated the effect of memory CD8+ T cell level on viral clearance and found
unsurprisingly that a high pre-existing level of memory CD8+ T cells was always beneficial.
However, our results suggest that pre-existing memory CD8+ T cells may be particularly ben-
eficial for certain groups of people. For example, if the memory CD8+ T cell number induced
by viral infection or vaccination is assumed to be relatively constant for everyone, people with
less naive CD8+ T cells would benefit more upon viral re-infection (see Fig. 8a). On the other
hand, if assuming pre-existing memory CD8+ T cell number is positively correlated with the
number of naive CD8+ T cells (simulated in Fig. 8b), people with more naive CD8+ T cells
would benefit more upon viral re-infection. Emerging evidence suggests that the relationship
between the level of memory CD8+ T cells and naive precursor frequencies is likely to be
deeply complicated (56, 70, 71, 72). In that context, our model predictions emphasize the im-
portance for further research in this area, and the necessity to take prior population immunity
into consideration when designing CD8+ T cell vaccines (64).
We modeled both short-lived and long-lived antibody responses. Experimental data and
model predictions consistently show that the short-lived antibody response results in a tem-
porary reduction in virus level whereas the long-lived antibody response is responsible for
complete viral clearance (Fig. 5). We emphasize here that although the model is able to capture
the observed short-lived and long-lived antibody responses (in order to study the virus-immune
response interactions), it is not designed to investigate the mechanisms inducing different an-
tibody responses. The observed difference in antibody decay profile may be a result of many
factors including the life times of different antibody-secreting cell types (73, 74), different an-
tibody life times (75) and antibody consumption through neutralizing free virions. Detailed
study of these phenomena requires a more detailed model and associated data for parameter
estimation and model validation, and is thus left for future work. Similarly, CD4+ T cells are
also known to perform a variety of functions in the development of immunity, such as facil-
itation of the formation and optimal recall of CD8+ T cells or even direct killing of infected
cells during viral infection (9, 10, 76, 77). Their depletion due to, say, HIV infection has also
been associated with more severe clinical outcomes following influenza infection (78). Some
of the major functions of CD4+ T cells may be considered to be implicitly modeled through
relevant parameters such as the rate of recall of memory CD8+ T cells (modeled by the delay
τCm) in our extended model which includes memory CD8+ T cells. However, a detailed viral
dynamics study of the role of CD4+ T cells in influenza infection, including in HIV infected
patients with depleted CD4+ T cells, remains an open and important challenge.
In a recent theoretical study, it was found that spatial heterogeneity in the T cell distribution
may influence viral clearance (42). Resident CD8+ T cells in the lungs have a more direct
and significant effect on timely viral clearance than do naive and memory pools resident in
lymph nodes. Although this factor has been partially taken into consideration in our model by
introducing a delay for naive/memory CD8+ T cells, lack of explicit modeling of the spatial
dynamics limits a direct application of our model to investigate these spatial effects.
Finally, as noted in the results, one of the influenza A(H7N9)-infected patients (patient
a79) was not included in our analysis of the clinical data (Fig. 7). Although our model suggests
some possibilities for the source of variation due to possible variation in parameter values, large
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variations in recovery time are only expected to occur for relatively low levels of naive CD8+ T
cells, nominally incompatible with this patient’s moderate CD8+ T cell response but a relatively
long recovery time. However, we note that IFNγ+ CD8+ T cell counts for this patient were
only collected at days 10 and 23, and that the count at day 10 was particularly low and much
lower than that at day 23 (see Dataset S1). We suspect that delayed, rather than weakened,
production (to at least day 10) of the IFNγ+ CD8+ T cell response in this patient substantially
contributed to the observed delay in recovery. Further investigation of this patient’s clinical
course and clinical samples is currently being undertaken.
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Par. Description Value & Unit Ref.
V0 initial viral load 104 [uV] estimated
T0 initial number of epithelial cells in the URT 7×107 cells (53)
gT base growth rate of healthy cells 0.8 d−1 fixed
pV viral production rate 210 [uV]cell−1d−1 estimated
pF IFN production rate 10−5 [uF]cell−1d−1 estimated
pC naive CD8+ T cell proliferation rate 1.2 d−1 (32)
pB naive B cell proliferation rate 0.52 d−1 estimated
pS short-lived antibody production rate 12 [uA]cell−1d−1 estimated
pL long-lived antibody production rate 4 [uA]cell−1d−1 estimated
δV nonspecific viral clearance rate 5 d−1 (47)
δI nonspecific death rate of infected cells 2 d−1 (32)
δF IFN degradation rate 2 d−1 (45)
δE death rate of effector CD8+ T cells 0.57 d−1 (59)
δP death rate of plasma B cells 0.5 d−1 estimated
δS short-lived antibody consumption rate 2 d−1 estimated
δL long-lived antibody consumption rate 0.015 d−1 estimated
β rate of viral consumption by binding to target cells 5×10−7 cell−1d−1 estimated
β ′ rate of infection of target cells by virus 3×10−8 [uV]−1d−1 estimated
φ rate of conversion to virus-resistant state 0.33 [uF]−1d−1 (45)
ρ rate of recovery from virus-resistant state 2.6 d−1 (45)
κS rate of viral neutralization by short-lived antibodies 0.8 [uA]−1d−1 estimated
κL rate of viral neutralization by long-lived antibodies 0.4 [uA]−1d−1 estimated
κN killing rate of infected cells by IFN-activated NK
cells
2.5 [uF]−1d−1 (45)
κE killing rate of infected cells by effector CD8+ T cells 5×10−5 cell−1d−1 estimated
βCn maximum rate of stimulation of naive CD8+ T cells
by virus
1 d−1 (9)
βBn maximum rate of stimulation of naive B cells by virus 0.03 d−1 estimated
hC half-maximal stimulating viral load for naive CD8+
T cells
104 [uV] estimated
hB half-maximal stimulating viral load for naive B cells 104 [uV] estimated
τC delay for effector CD8+ T cell production 6 d (51)
τB delay for plasma B cell production 4 d estimated
Table 1: Model parameter values obtained by fitting the model to experimental data. [uV ],
[uF ] and [uA] represent the units of viral load, IFN and antibodies respectively. [uV ] and [uA]
are EID50/ml (50% egg infective dose) and pg/ml, consistent with the units of data. IFN is
assumed to be a non-dimensionalized variable in the model, and therefore [uF ] can be ignored.
Some parameters are obtained from the literature and the rest are obtained by fitting the model
to experimental data in the paper of Miao et al. (38), except gT which is of minor importance
when considering a single infection and is thus fixed to reduce uncertainty.
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0.1 Numerical method for solving the model
The delay in activation of CD8+ T cells and B cells directly results in the delay of production
of effector CD8+ T cells and antibody-producing cells. By a time-shift transform t = t ′+ τC,
Eq. 7 in the main text becomes
dE(t ′+ τC)
dt ′ = βCn(
V (t ′)
V (t ′)+hC
)Cn(t ′)e(pCτC)−δEE(t ′+ τC), (S1)
where t ≥ 0 and t ′ starts from −τC. As defined in the main text, V = 0 for any negative time,
i.e. V (t ′) = 0 for −τC < t ′ < 0. Moreover, E(t ′+τC) = 0 for τC < t ′ < 0. Thus, the equation is
trivial for t ′ ≥ 0. Therefore, for t ′ ≥ 0, we replace t ′ back to t and Eq. S1 becomes
dE(t + τC)
dt = βCn(
V (t)
V (t)+hC
)Cn(t)e(pCτC)−δEE(t + τC), (S2)
where t ≥ 0. Similarly, Eqs. 9-11 in the main text can be changed to
dP(t + τB)
dt = βBn(
V (t)
V (t)+hB
)Bn(t)e(pBτB)−δPP(t + τB), (S3)
dAS(t + τB)
dt = pSP(t + τB)−δSAS(t + τB), (S4)
dAL(t + τB)
dt = pLP(t + τB)−δLAL(t + τB), (S5)
In this way, the model presented in the main text is equivalent to the following model:
dV
dt = pV I−δVV −κSVAS(t)−κLVAL(t)−βVT, (S6)
dT
dt = gT (T +R)(1−
T +R+ I
T0
)−β ′VT +ρR−φFT, (S7)
dI
dt = β
′VT −δII−κNIF−κE IE(t), (S8)
dF
dt = pF I−δFF, (S9)
dR
dt = φFT −ρR, (S10)
dCn
dt =−βCn(
V
V +hC
)Cn, (S11)
dE(t + τC)
dt = βCn(
V
V +hC
)Cne(pCτC)−δEE(t + τC), (S12)
dBn
dt =−βBn(
V
V +hB
)Bn, (S13)
dP(t + τB)
dt = βBn(
V
V +hB
)Bne(pBτB)−δPP(t + τB), (S14)
dAS(t + τB)
dt = pSP(t + τB)−δSAS(t + τB), (S15)
dAL(t + τB)
dt = pLP(t + τB)−δLAL(t + τB). (S16)
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For variables whose independent variable is not explicitly specified, they are all functions of t,
i.e. V reads V (t). This model avoids negative time and is solved by the following steps:
• Firstly choosing a time step size ∆t and using it to discretise the time domain to be
t = 0,∆t,2∆t,3∆t, ...,N∆t. The results in the main text are generated using ∆t = 0.1
(day), the choice of which is based on the result that further decreasing ∆t does not
improve the solution (results not shown).
• Given initial condition
(V,T, I,F,R,Cn,E,Bn,P,AS,AL) = (V0,7×107,0,0,0,100,0,100,0,0,0),
we solve the model iteratively. For iteration from k∆t to (k + 1)∆t, AS(t), AL(t) and
E(t) in Eqs. S6 and S8 are already known and thus treated as parameters. The system
becomes an ODE system and can be easily solved by using a built-in ODE solver ode15s
in MATLAB(R2014b) with default settings. All the variables at time (k+1)∆t are then
updated for use in the next iteration.
MATLAB code is provided below.
1 c l e a r
2 d t = 0 . 1 ; % t im e s t e p s i z e
3 t im e =0: d t : 1 0 0 ;
4
5 % p a r a m e t e r s
6 T0=7e +7; gT = 0 . 8 ; pV=210; d e l t a V = 5 . 0 ;
7 b e t a =5e−7; b e t a p =3e−8;
8 d e l t a I =2; kappaN = 2 . 5 ; kappaE=5e−5;
9 p h i = 0 . 3 3 ; rho = 2 . 6 ; pF=1e−5; d e l t a F =2;
10 betaCn =1; betaBn = 0 . 0 3 ;
11 kappaS = 0 . 8 ; kappaL = 0 . 4 ;
12 pC = 1 . 2 ; pB = 0 . 5 2 ; d e l t a E = 0 . 5 7 ; d e l t a P = 0 . 5 ;
13 pS =12; pL =4; d e l t a S =2; d e l t a L = 0 . 0 1 5 ;
14 tauC =6; tauB =4; hC=1e +4; hB=1e +4;
15
16 % i n d e x i n d i c a t i n g when d e l a y e d p r o c e s s s t a r t s
17 indC= round ( tauC / d t +1) ; % f o r tauC
18 indB= round ( tauB / d t +1) ; % f o r tauB
19
20 % v a r i a b l e v e c t o r s and i n i t i a l c o n d i t i o n s
21 V= z e r o s ( 1 , l e n g t h ( t im e ) ) ;V( 1 ) =1e +4;
22 T=V; T ( 1 ) =7e +7;
23 I =T ; I ( 1 ) =0;
24 R= I ;
25 F= I ;
26 Cn=100∗ ones ( 1 , l e n g t h ( t im e ) ) ;
27 Bn=100∗ ones ( 1 , l e n g t h ( t im e ) ) ;
28 E= z e r o s ( 1 , indC+ l e n g t h ( t im e ) ) ;
29 P= I ;
30 AS= z e r o s ( 1 , indB+ l e n g t h ( t im e ) ) ;
31 AL=AS ;
27
32
33 i n i t =[V( 1 ) ,T ( 1 ) , I ( 1 ) ,R ( 1 ) , F ( 1 ) ,Cn ( 1 ) ,E ( 1 ) , Bn ( 1 ) , P ( 1 ) ,AS ( 1 ) ,AL
( 1 ) ] ’ ;
34
35 o p t i o n s = o d e s e t ( ’ Re lTo l ’ ,1 e−3, ’ AbsTol ’ ,1 e−6) ;
36
37 f o r i =2: l e n g t h ( t im e )
38 [ ˜ ,Y]= ode15s ( @ODEmodel , [ 0 d t ] , i n i t , o p t i o n s , E ( i ) ,AL( i ) ,AS( i
) , tauC , tauB , phi , rho , d e l t a F , gT , pF , pV , be t a , be t ap , kappaN ,
de l t aV , d e l t a I , betaCn , betaBn , kappaE , kappaS , pL , pS , d e l t a L ,
d e l t a S , d e l t a P , d e l t a E , pC , pB , kappaL , hC , hB , T0 ) ;
39
40 V( i ) =Y( end , 1 ) ; T ( i ) =Y( end , 2 ) ; I ( i ) =Y( end , 3 ) ; R( i ) =Y( end , 4 ) ;
41 F ( i ) =Y( end , 5 ) ; Cn ( i ) =Y( end , 6 ) ; Bn ( i ) =Y( end , 8 ) ; P ( i ) =Y( end , 9 ) ;
42 E ( indC+ i ) =Y( end , 7 ) ;
43 AS( indB+ i ) =Y( end , 1 0 ) ;
44 AL( indB+ i ) =Y( end , 1 1 ) ;
45
46 i n i t =Y( end , : ) ’ ; % i n i t i a l c o n d i t i o n f o r n e x t i t e r a t i o n
47 end
In the command of ode15s, a function “ODEmodel” is required and provided below.
1 f u n c t i o n ynew=ODEmodel ( ˜ , y , E , AL, AS , tauC , tauB , phi , rho , d e l t a F , gT
, pF , pV , be t a , be t ap , kappaN , de l t aV , d e l t a I , betaCn , betaBn , kappaE ,
kappaS , pL , pS , d e l t a L , d e l t a S , d e l t a P , d e l t a E , pC , pB , kappaL , hC , hB ,
T0 )
2
3 % V: v i r a l l o a d
4 % T : t a r g e t c e l l
5 % I : i n f e c t e d c e l l
6 % R: R e s i s t a n t c e l l
7 % F : IFN
8 % Cn : n a i v e CD8+ T c e l l s
9 % E : e f f e c t o r CD8+ T c e l l s
10 % Bn : n a i v e B c e l l s
11 % P : plasma B c e l l s
12 % AS : s h o r t−l i v e d a n t i b o d i e s
13 % AL: long−l i v e d a n t i b o d i e s
14
15 % y =[V, T , I , R , F , Cn , E , Bn , P , AS , AL]
16
17 ynew= z e r o s ( 1 1 , 1 ) ;
18
19 ynew ( 1 ) =pV∗y ( 3 )−d e l t a V ∗y ( 1 )−kappaS ∗y ( 1 ) ∗AS−kappaL∗y ( 1 ) ∗AL−b e t a
∗y ( 1 ) ∗y ( 2 ) ;
20 ynew ( 2 ) =gT ∗ ( y ( 2 ) +y ( 4 ) ) ∗(1−( y ( 2 ) +y ( 3 ) +y ( 4 ) ) / T0 )−b e t a p ∗y ( 1 ) ∗y ( 2 )
+ rho ∗y ( 4 )−p h i ∗y ( 2 ) ∗y ( 5 ) ;
28
21 ynew ( 3 ) = b e t a p ∗y ( 1 ) ∗y ( 2 )−d e l t a I ∗y ( 3 )−kappaN∗y ( 3 ) ∗y ( 5 )−kappaE∗y
( 3 ) ∗E ;
22 ynew ( 4 ) = p h i ∗y ( 2 ) ∗y ( 5 )−rho ∗y ( 4 ) ;
23 ynew ( 5 ) =pF∗y ( 3 )−d e l t a F ∗y ( 5 ) ;
24 ynew ( 6 )=−betaCn ∗y ( 1 ) / ( y ( 1 ) +hC ) ∗y ( 6 ) ;
25 ynew ( 7 ) = betaCn ∗y ( 1 ) / ( y ( 1 ) +hC ) ∗y ( 6 ) ∗ exp ( pC∗ tauC )−d e l t a E ∗y ( 7 ) ;
26 ynew ( 8 )=−betaBn ∗y ( 1 ) / ( y ( 1 ) +hB ) ∗y ( 8 ) ;
27 ynew ( 9 ) = betaBn ∗y ( 1 ) / ( y ( 1 ) +hB ) ∗y ( 8 ) ∗ exp ( pB∗ tauB )−d e l t a P ∗y ( 9 ) ;
28 ynew ( 1 0 ) =pS∗y ( 9 )−d e l t a S ∗y ( 1 0 ) ;
29 ynew ( 1 1 ) =pL∗y ( 9 )−d e l t a L ∗y ( 1 1 ) ;
29
0.2 Details of fitting the model to data
The model contains 11 equations and 30 parameters (see Table 1 in the main text). This rep-
resents a serious challenge in terms of parameter estimation, and clearly prevents a straightfor-
ward application of standard statistical techniques. However, based on an extensive survey of
the experimental literature, we have been able to identify plausible, but by no means unique,
combinations of parameters that successfully explain the available data. A number of param-
eters were taken directly from the literature, as per the citations in Table 1. The rest (18 pa-
rameters) were estimated by calibrating the model to the published data from Miao et al. (38)
who measured viral titre, CD8+ T cell counts and IgM and IgG antibodies in laboratory mice
(exhibiting a full immune response) over time during primary influenza H3N2 virus infection
(shown in Fig. 2 in the main text). Note that the data were presented in scatter plots in the
original paper (38), while we presented the data in Mean ± SD at each data collection time
point (as shown in Fig. 2 in the main text) and fit our mean-field mathematical model to the
means.
To obtain the set of parameters used for the main analysis from the experimental data in the
paper of Miao et al. (38), we took the following approach:
• We first manually determined a set of the 18 parameters which produced a model solution
that reasonably matched the experimental data shown in Fig. 2 in the main text. In detail,
the main criteria include: 1) the viral load starts from about 104EID50/ml, reaches a
peak of about 107EID50/ml at 1–2 days p.i., then declines rapidly from about 5 days p.i.
(note that the last three data points were not considered due to the limit of detection);
2) the CD8+ T cell count starts to increase rapidly at about 6 days p.i., reaches a peak
of about 105–106 at 8–10 days p.i. and returns back to zero after about 20 days p.i.; 3)
the IgM level starts to increase rapidly at 4–5 days p.i., reaches a peak of about 200–
300 pg/ml at about 10 days p.i. and returns back to baseline after about 20 days p.i.;
4) the IgG level starts to increase rapidly at 4–5 days p.i., reaches a peak of about 800–
1000 pg/ml at about 20 days p.i. and decays slowly. Given the high-dimensionality of the
parameter space and limited experimental data, the procedure was essential in allowing us
to identify a candidate parameter set which was not far from generating a local minimum
in the following optimisation process.
• The candidate parameter set was then used as an initial estimate for optimization using
MATLAB’s built-in function fmincon with default settings. The target of optimization
was to minimize the least-squares error (LSE):
L = LV +LE +LM +LG, (S17)
where the four LSE components for viral load, effector CD8+ T cells, IgM and IgG were
given respectively by
LV = ∑
i
[(Vmodel(ti)−Vdata(ti))wV (ti)/sV ]2, (S18)
LE = ∑
i
[(Emodel(ti)−Edata(ti))wE(ti)/sE ]2, (S19)
LM = ∑
i
[(Mmodel(ti)−Mdata(ti))wM(ti)/sM]2, (S20)
LG = ∑
i
[(Gmodel(ti)−Gdata(ti))wG(ti)/sG]2. (S21)
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Vmodel , Emodel , Mmodel and Gmodel indicate the model solution for variables V , E, AS and
AL evaluated at time ti respectively. Vdata, Edata, Mdata and Gdata indicate the associated
data. i is the index of the time point and the ti may differ for the four components.
sV = 107, sE = 6×104, sM = 300 and sG = 900 were used to scale the errors to the same
order of magnitude. Due to the fact that data were not collected at a fixed frequency
(i.e. the time interval between adjacent data points is not constant), the errors at different
time points were assigned different weights based on the length of time intervals between
adjacent points. For example, if viral load was measured at time ti,(i = 0,1,2, ...,k), the
weight function wV (ti) for interior points was given by
wV (ti) =
ti+1− ti−1
2(tk− t0)
, (S22)
and for boundary points by
wV (t0) =
t1− t0
2(tk− t0)
and wV (tk) =
tk− tk−1
2(tk− t0)
. (S23)
This error weighting was used to weaken the domination of dense data points on model
fits. It is evident that a lot of measurements were done within the first 10 days post-
infection but only a few were performed after day 20 post-infection, in particular for IgG
data (see Fig. 2 in the main text). We found that using equally weighted LSEs led to a
model fit that manifestly failed to capture those sparse data points which we believe are
equally, if not more important from a more biological perspective, in determining the IgG
kinetics (see Fig. S8, compared with Fig. 2 in the main text).
• The parameter constraints when using fmincon were set to V0 ∈ [103,105], pV ∈ [50,500],
β ∈ [0,1], β ′ ∈ [0,1], pF ∈ [0,1], κS ∈ [0,2], κL ∈ [0,1], κE ∈ [0,1], βBn∈ [0,2], pB ∈ [0,1],
δP ∈ [0,1], δS ∈ [0,5], pS ∈ [0,20], pL ∈ [0,20], δL ∈ [0,0.1], τB ∈ [3,7], hC ∈ [103,105]
and hB ∈ [103,105].
• After obtaining a locally optimized solution for the candidate parameter set, we then
checked the solution generated and evaluated its biological plausibility (based on the
criteria mentioned above). This step was essential as given the over-specification of the
model (in a statistical sense), it was possible for good fitting solutions to be identified by
MATLAB’s optimization algorithm, which were nonetheless biologically implausible.
For example, oscillatory solutions for quantities such as IgG, while providing a “good-
fit” to data, were not deemed acceptable on biological grounds (see Fig. S9 for such an
example). If the optimised solution failed our (qualitative) evaluation, we returned to
the first step and redetermined a new set of parameters as new initial estimates to be
optimized using MATLAB.
This entire process was repeated to arrive at the default parameter set shown in Table 1 in
the main text. To guarantee that the default parameter set was a good choice, we further ran-
domly generated 10,000 sets of parameter samples near the default parameter set (within±50%
from the default values) and used them as initial estimates with fmincon to search for locally
optimized solutions. Of these, 31 generated a better LSE but all failed to meet the criteria
mentioned above (results not shown).
Fig. 2 in the main text shows how the model reproduces the key dynamic behavior shown in
the data. We also show in the Results section in the main text, that the model behavior is robust
to perturbation of model parameters and that model predictions are reasonably consistent with
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a range of other experimental data, demonstrating the plausibility, if not uniqueness (of course),
of the parameter set. We emphasize that, although the default parameter set is successful in re-
producing a multitude of experimental observations (e.g. full immune, knockout, re-infection)
as presented in the main text, we by no means claim that this parameter set is unique. It remains
an open and challenging problem to reliably identify a biologically plausible and statistically
identifiable solution for what is a highly complex system, where we are severely limited by
available experimental data.
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0.3 The model with memory CD8+ T cells
Incorporating memory CD8+ T cells into the model in the main text, we only make two
changes. The first is adding two equations to describe the memory CD8+ T cell (Cm) pro-
liferation/differentiation, similar to Eqs. 6 and 7 in the main text
dCm
dt =−βCm(
V
V +hCm
)Cm, (S24)
dEm
dt = βCm(
V (t− τCm)
V (t− τCm)+hCm
)Cm(t− τCm)e(pCmτCm)−δEEm. (S25)
Then we change the term κEIE in Eq. 3 in the main text to κEI(E +Em). Hence, similar to the
approach mentioned above that moving the delayed term from viral load to effector cells, we
write down the model in an equivalent form,
dV
dt = pV I−δVV −κSVAS(t)−κLVAL(t)−βVT, (S26)
dT
dt = gT (T +R)(1−
T +R+ I
T0
)−β ′VT +ρR−φFT, (S27)
dI
dt = β
′VT −δII−κNIF−κE I[E(t)+Em(t)], (S28)
dF
dt = pF I−δFF, (S29)
dR
dt = φFT −ρR, (S30)
dCn
dt =−βCn(
V
V +hC
)Cn, (S31)
dE(t + τC)
dt = βCn(
V
V +hC
)Cne(pCτC)−δEE(t + τC), (S32)
dBn
dt =−βBn(
V
V +hB
)Bn, (S33)
dP(t + τB)
dt = βBn(
V
V +hB
)Bne(pBτB)−δPP(t + τB), (S34)
dAS(t + τB)
dt = pSP(t + τB)−δSAS(t + τB), (S35)
dAL(t + τB)
dt = pLP(t + τB)−δLAL(t + τB). (S36)
dCm
dt =−βCm(
V
V +hCm
)Cm, (S37)
dEm(t + τCm)
dt = βCm(
V
V +hCm
)Cme(pCmτCm)−δEEm(t + τCm). (S38)
For variables whose independent variables are not explicitly specified, they are all functions
of t, i.e. V reads V (t). Memory CD8+ T cells show a shorter delay and faster proliferation than
naive CD8+ T cells (59). The shortened delay may be caused by a shortened lag time to the first
division and/or a reduced delay for effector cells migrating from the lymphatic compartment
to the lung (59, 36, 42). The former reduction is about 15 hours (59) and the latter is less than
about 12 hours (36). Thus, we choose τCm = 5 (days), correspond to a one day reduction in
the delay time compared to the delay of naive cells (τC = 6). Memory CD8+ T cells show a
33
higher division rate and a lower loss rate than naive CD8+ T cells (59), based on which the net
production rate of effector cells for memory CD8+ T cells is estimated to be about 1.5 times
of that for naive cells. Thus,we choose pCm = 1.5pC = 1.8 (day−1). In the absence of data,
we assume βCm = βC and hCm = hC. The initial number of memory CD8+ T cells is varied as
specified in the main text or figures. We assume that the effector CD8+ T cells produced by
either naive or memory CD8+ T cells are functionally identical (i.e. then have the same decay
rate δE and killing rate κE). Note that we do not model the process of differentiation of effector
CD8+ T cells into memory cells but use a memory cell pool as an initial condition to simulate
viral re-infection.
MATLAB code is provided below.
1 c l e a r
2 d t = 0 . 1 ; % t im e s t e p s i z e
3 t im e =0: d t : 1 0 0 ;
4 % p a r a m e t e r s
5 T0=7e +7; gT = 0 . 8 ; pV=210; d e l t a V = 5 . 0 ;
6 b e t a =5e−7; b e t a p =3e−8;
7 d e l t a I =2; kappaN = 2 . 5 ; kappaE=5e−5;
8 p h i = 0 . 3 3 ; rho = 2 . 6 ; pF=1e−5; d e l t a F =2;
9 betaCn =1; betaBn = 0 . 0 3 ;
10 kappaS = 0 . 8 ; kappaL = 0 . 4 ;
11 pC = 1 . 2 ; pB = 0 . 5 2 ; d e l t a E = 0 . 5 7 ; d e l t a P = 0 . 5 ;
12 pS =12; pL =4; d e l t a S =2; d e l t a L = 0 . 0 1 5 ;
13 tauC =6; tauB =4; hC=1e +4; hB=1e +4;
14 betaCm =1;pCm = 1 . 8 ; tauCm =5;
15
16 % i n d e x i n d i c a t i n g when d e l a y e d p r o c e s s s t a r t s
17 indC= round ( tauC / d t +1) ; % f o r tauC
18 indCm= round ( tauCm / d t +1) ; % f o r tauCm
19 indB= round ( tauB / d t +1) ; % f o r tauB
20
21 % v a r i a b l e v e c t o r s and i n i t i a l c o n d i t i o n s
22 V= z e r o s ( 1 , l e n g t h ( t im e ) ) ;V( 1 ) =1e +1;
23 T=V; T ( 1 ) =7e +7; I =T ; I ( 1 ) =0;R= I ; F= I ;
24 Cn=100∗ ones ( 1 , l e n g t h ( t im e ) ) ;
25 Bn=100∗ ones ( 1 , l e n g t h ( t im e ) ) ;
26 E= z e r o s ( 1 , indC+ l e n g t h ( t im e ) ) ;
27 P= I ; AS= z e r o s ( 1 , indB+ l e n g t h ( t im e ) ) ;AL=AS ;
28 Cm=5000∗ ones ( 1 , l e n g t h ( t im e ) ) ;
29 Em= z e r o s ( 1 , indCm+ l e n g t h ( t im e ) ) ;
30
31 i n i t =[V( 1 ) ,T ( 1 ) , I ( 1 ) ,R ( 1 ) , F ( 1 ) ,Cn ( 1 ) ,E ( 1 ) , Bn ( 1 ) , P ( 1 ) ,AS ( 1 ) ,AL
( 1 ) ,
32 Cm( 1 ) ,Em( 1 ) ] ’ ;
33
34 o p t i o n s = o d e s e t ( ’ Re lTo l ’ ,1 e−3, ’ AbsTol ’ ,1 e−6) ;
35
36 f o r i =2: l e n g t h ( t im e )
37 [ ˜ ,Y] = ode15s ( @ODEmodel with memory , [ 0 d t ] , i n i t , o p t i o n s , E
34
( i ) ,AL( i ) ,AS( i ) ,Em( i ) , tauC , tauB , phi , rho , d e l t a F , gT , pF , pV ,
be t a , be t ap , kappaN , de l t aV , d e l t a I , betaCn , betaBn , kappaE ,
kappaS , pL , pS , d e l t a L , d e l t a S , d e l t a P , d e l t a E , pC , pB , kappaL , hC
, hB , T0 , betaCm , pCm , tauCm ) ;
38
39 V( i ) =Y( end , 1 ) ; T ( i ) =Y( end , 2 ) ; I ( i ) =Y( end , 3 ) ; R( i ) =Y( end , 4 ) ;
40 F ( i ) =Y( end , 5 ) ; Cn ( i ) =Y( end , 6 ) ; Bn ( i ) =Y( end , 8 ) ; P ( i ) =Y( end , 9 ) ;
41 E ( indC+ i ) =Y( end , 7 ) ;
42 AS( indB+ i ) =Y( end , 1 0 ) ;AL( indB+ i ) =Y( end , 1 1 ) ;
43 Cm( i ) =Y( end , 1 2 ) ;Em( indCm+ i ) =Y( end , 1 3 ) ;
44 i n i t =Y( end , : ) ’ ; % i n i t i a l c o n d i t i o n f o r n e x t i t e r a t i o n
45 end
The function “ODEmodel with memory” is provided below.
1 f u n c t i o n ynew=ODEmodel New with memory ( ˜ , y , E , AL, AS , Em, tauC ,
tauB , phi , rho , d e l t a F , gT , pF , pV , be t a , be t ap , kappaN , de l t aV , d e l t a I
, betaCn , betaBn , kappaE , kappaS , pL , pS , d e l t a L , d e l t a S , d e l t a P ,
d e l t a E , pC , pB , kappaL , hC , hB , T0 , betaCm , pCm , tauCm )
2
3 % V: v i r a l l o a d
4 % T : t a r g e t c e l l
5 % I : i n f e c t e d c e l l
6 % R: R e s i s t a n t c e l l
7 % F : IFN
8 % Cn : n a i v e CD8+ T c e l l s
9 % E : e f f e c t o r CD8+ T c e l l s
10 % Bn : n a i v e B c e l l s
11 % P : plasma B c e l l s
12 % AS : s h o r t−l i v e d a n t i b o d i e s
13 % AL: long−l i v e d a n t i b o d i e s
14 % Cm: memory CD8+ T c e l l s
15 % Em: e f f e c t o r CD8+ T c e l l s p roduced from memory c e l l s
16
17 % y =[V, T , I , R , F , Cn , E , Bn , P , AS , AL,Cm,Em]
18
19 ynew= z e r o s ( 1 3 , 1 ) ;
20 ynew ( 1 ) =pV∗y ( 3 )−d e l t a V ∗y ( 1 )−kappaS ∗y ( 1 ) ∗AS−kappaL∗y ( 1 ) ∗AL−b e t a
∗y ( 1 ) ∗y ( 2 ) ;
21 ynew ( 2 ) =gT ∗ ( y ( 2 ) +y ( 4 ) ) ∗(1−( y ( 2 ) +y ( 3 ) +y ( 4 ) ) / T0 )−b e t a p ∗y ( 1 ) ∗y ( 2 )
+ rho ∗y ( 4 )−p h i ∗y ( 2 ) ∗y ( 5 ) ;
22 ynew ( 3 ) = b e t a p ∗y ( 1 ) ∗y ( 2 )−d e l t a I ∗y ( 3 )−kappaN∗y ( 3 ) ∗y ( 5 )−kappaE∗y
( 3 ) ∗ (E+Em) ;
23 ynew ( 4 ) = p h i ∗y ( 2 ) ∗y ( 5 )−rho ∗y ( 4 ) ;
24 ynew ( 5 ) =pF∗y ( 3 )−d e l t a F ∗y ( 5 ) ;
25 ynew ( 6 )=−betaCn ∗y ( 1 ) . / ( y ( 1 ) +hC ) ∗y ( 6 ) ;
26 ynew ( 7 ) = betaCn ∗y ( 1 ) . / ( y ( 1 ) +hC ) ∗y ( 6 ) ∗ exp ( pC∗ tauC )−d e l t a E ∗y ( 7 ) ;
27 ynew ( 8 )=−betaBn ∗y ( 1 ) . / ( y ( 1 ) +hB ) ∗y ( 8 ) ;
28 ynew ( 9 ) = betaBn ∗y ( 1 ) . / ( y ( 1 ) +hB ) ∗y ( 8 ) ∗ exp ( pB∗ tauB )−d e l t a P ∗y ( 9 ) ;
35
29 ynew ( 1 0 ) =pS∗y ( 9 )−d e l t a S ∗y ( 1 0 ) ;
30 ynew ( 1 1 ) =pL∗y ( 9 )−d e l t a L ∗y ( 1 1 ) ;
31 ynew ( 1 2 )=−betaCm∗y ( 1 ) . / ( y ( 1 ) +hC ) ∗y ( 1 2 ) ;
32 ynew ( 1 3 ) =betaCm∗y ( 1 ) . / ( y ( 1 ) +hC ) ∗y ( 1 2 ) ∗ exp (pCm∗ tauCm )−d e l t a E ∗y
( 1 3 ) ;
36
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FIGURE S1: Model solution with parameters given in Table 1 in the main text shows that the loss of
uninfected epithelial cells is maintained within 10–20% of total cell pool. This number of uninfected
epithelial cells equals the sum of target cells T and resistant cells R shown in Fig. 3 in the main text.
time (days)
0 2 4 6 8 10
lo
g
1
0
(V
) 
(E
ID
5
0
/m
l)
0
2
4
6
8
10
viral load
target cell number
time (days)
0 2 4 6 8 10
lo
g
1
0
(V
) 
(E
ID
5
0
/m
l)
0
2
4
6
8
10
viral load
target cell number
(a) (b)
FIGURE S2: Inclusion of IFN prevents target cell depletion. In the absence of adaptive immunity
(letting Cn = Bn = 0 in the model), the model with IFN production (pF = 10−5) simulates a sustained
elevation of viral load and large steady state target cell number (dashed curve in panel (a)), both of
which are consistent with previous experimental data (shown in Fig. 5 in the main text). However, in the
absence of an innate response (letting pF = 0), panel (b) shows that target cells are depleted, inducing a
rapid fall in viral load. Note that for target cell number, the y-axis indicates log10(target cell number).
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FIGURE S3: The three-phase model behavior is robust to the change of parameters. By allowing all
the parameters to vary by ±20% from their default values (i.e. those shown in Table 1), 1000 samples
of parameter sets were selected using Latin hypercube sampling and 1000 corresponding viral load
solutions are shown in the upper panel. In Fig. 4 in the main text, we illustrated the phase separation
using area shading. Here, the rough times of phase separation are indicated by the histograms in the
lower panel; the left one indicates the time separating the first and the second phases (i.e. the time when
the corresponding solutions of “full immune” and “no immunity” differ by 0.2 (in log-scale) for the first
time) and right one indicates the time separating the second and the third phases (i.e. the time when the
corresponding solutions of “full immune” and “IFN only” differ by 0.2 (in log-scale) for the first time).
The solutions of “no immunity” are obtained by letting pF = 0 and βCn = βBn = 0 in the model, and the
solutions of “IFN only” are obtained by letting βCn = βBn = 0 in the model.
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FIGURE S4: Dependence of model behaviour on the production rate of CD8+ T cells (panel (a)),
short-lived antibodies (panel (b)) and long-lived antibodies (panel (c)). Different levels of production
for CD8+ T cells, short-lived and long-lived antibodies are modelled respectively by varying the naive
CD8+ T cell number (Cn), short-lived antibody production rate (pS) and long-lived antibody production
rate (pL). For each panel, all other model parameters were kept fixed at the values given in Table 1 in
the main text.
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FIGURE S5: Dependence of the average effector CD8+ T cell number (over days 6–20) on the delay
induced by naive CD8+ T cell activation and differentiation (τC). Recovery time is defined to be the
time when viral load falls to 1 EID50/ml. Panel (a) shows that the average effector CD8+ T cell number
is exponentially related to the delay τC. Panel (b) shows that the recovery time is related to the delay
τC in an approximately piecewise linear manner. Panel (c) shows varying delay τC also preserves the
approximately exponential relationship between the average CD8+ T cell numbers and recovery time,
consistent with the results of varying initial naive CD8+ T cell numbers shown in Fig. 6 in the main
text.
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FIGURE S6: The exponential relationship between recovery time and the average effector CD8+ T cell
number (over days 6–20) is robust to the changes in the viral production rate pV . Recovery time is
defined to be the time when the viral load falls to 1 EID50/ml. For each pV , the relationship between
average CD8+ T cells and recovery time was obtained by varying initial naive CD8+ T cell number.
Except for large pV (e.g. pV = 350,400), all other cases are well fit by exponential curves (thin black
curves through the simulated data). When pV is large (the cases of pV = 350,400), we observe a de-
viation from the exponential relationship for low expression of effector CD8+ T cells. For example a
decrease in recovery time is observed for a lower level of effector CD8+ T cells (in the range of less
than 5000 cells) for pV = 400, whose reason is not clear and is likely a by-product of the highly complex
dynamical system.
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FIGURE S7: The exponential relationship between recovery time and the average effector CD8+ T cell
number (over days 6–20) is robust to the change of IFN production rate pF . Recovery time is defined to
be the time when viral load falls to 1 EID50/ml. The thin black curves through the simulated data are
exponential fits. One may observe that the recovery time increases and then decreases as pF increases.
The reason is not entirely clear. Our explanation is that the increase for small pF is likely because
increasing pF reduces the extent of target cell depletion and thus makes infection longer. When pF is
sufficiently large, a further increase in pF has little effect on target cell pool but induces stronger innate
immune response, which play a role in shortening the recovery time.
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FIGURE S8: An example of a best-fit solution failing to capture the sparse part of the IgG data very
well. Black dots are experimental data from (38) and black curves are the fits. The fit was generated
by using equally weighted LSE function (scale factors remain unchanged) and the parameters in Table
1 in the main text as an initial guess in MATLAB’s fmincon function. Compared to using weighted LSE
(which generates the fit shown by green dashed curves), using equally weighted LSE does not alter the
fits to the viral load and CD8+ T cell number but significant underestimates antibody levels. Note that
due to the limit of detection for the viral load (occurring after 10 days post-infection as seen in viral
load data), the last three data points in the upper-left panel were not taken into consideration for model
fitting.
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FIGURE S9: An example of a best-fit solution exhibiting oscillatory IgG, which was deemed biologi-
cally implausible. Black dots are experimental data from (38) and black curves are the fits. In fact, the
LSE for this fit is smaller than that generated by the estimates in Table 1 in the main text. But given
the fact that a few aspects of data were not well captured by this fit (indicated by dashed ovals), we
did not consider this fit as an acceptable solution. Note that due to the limit of detection for the viral
load (occurring after 10 days post-infection as seen in viral load data), the last three data points in the
upper-left panel were not taken into consideration for model fitting.
